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Abstract
Background: Transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma
(HCC) is an important option as the majority of patients present with advanced disease. Data regarding
treatment outcomes in patients who have undergone transjugular intrahepatic portosystemic shunts
(TIPS) are limited. The present study seeks to evaluate the safety and efficacy of TACE in HCC patients
with a TIPS.
Methods: A retrospective review identifying patients with HCC and concomitant TIPS who were trea-
ted with TACE was performed.
Results: From 1999 to 2014, 16 patients with HCC underwent a total of 27 TACE procedures; eight
patients required multiple treatments. The median patient age at the time of the initial TACE was
60.5 years [interquartile range (IQR) : 52.5–67.5] with the majority being male (n = 12, 75%) and
Childs–Pugh Class B (n = 12, 75%). At 6 weeks after TACE, 56.3% of patients achieved an objective
response rate (complete and partial response) by mRECIST criteria. Clavien Grade 3 or higher compli-
cations occurred in 11.1% of TACE procedures. There were no peri-procedural deaths. The median
progression-free (PFS) and overall survival (OS) were 9 and 22 months, respectively, when censored
for liver transplantation (median follow-up: 11.5 months).
Conclusion: TACE is an effective treatment strategy for HCC in TIPS patients; albeit may be associ-
ated with higher complication rates.
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Introduction
Transarterial chemoembolization (TACE) has emerged as an
effective treatment strategy for patients with hepatocellular car-
cinoma (HCC).1,2 Unlike surgery or transplantation, which are
dependent on patients having a resectable disease or the avail-
ability of suitable organs, studies have demonstrated TACE to
be effective for patients with advanced disease.3 However,
TACE is not without its limitations, as current treatment
guidelines recommend patients have compensated liver disease
along with overall good performance status when considering
this approach.4,5 The presence of cirrhosis and its associated
complications from portal hypertension, which include variceal
bleeding and ascites, often complicates decision-making and
traditionally may preclude a patient from receiving TACE.
Placement of transjugular intrahepatic portosystemic shunts
(TIPS) has become a widely used technique in managing the
sequelae of portal hypertension. However, as TIPS reduces
hepatic perfusion by diverting portal venous flow and may
potentiate arterioportal shunting, TACE has not been com-
monly performed in this subgroup owing to concern for
potential worsening of hepatic dysfunction, a transient increase
in portal hypertension and the risk of hepatic infarct.6,7 Unfor-
tunately with the rising incidence of HCC among western
countries, there has been a corresponding increase in the
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number of HCC cases with TIPS in need of loco-regional
therapy.8 In recent years, several studies have investigated the
feasibility of TACE in patients with a functional TIPS.6,9–14
While all the studies were limited by a small sample size, the
rates of TACE-related complications are variable (5–70%).
Owing to the paucity of data surrounding this subject and the
need to identify a viable treatment option for this patient
subgroup, the present study seeks to evaluate the safety and
efficacy of TACE for HCC patients after TIPS placement.
Patients and methods
Approval was first obtained from the Institutional Review
Board at the Medical College of Wisconsin. Using a prospec-
tively maintained database, patients diagnosed with HCC by
alpha-fetoprotein (AFP) levels, needle biopsy or diagnostic
radiographic criteria along with concomitant TIPS were identi-
fied. Inclusion criteria required that all patients underwent tar-
geted chemoembolization from 1999 to 2014. Patients who
received TACE prior to TIPS placement, or subsequently
underwent other liver-directed therapies, transplantation or
pursued surgical resection prior to follow-up imaging post
TACE were excluded. Standard clinicopathological data were
abstracted, which included the aetiology of the underlying liver
disease, an indication for TIPS, liver function tests (total biliru-
bin, AST/ALT, albumin), creatinine, platelet count, interna-
tional normalized ratio (INR), AFP and parameters of
advanced liver disease (presence of encephalopathy, ascites or
asterixis). Model for End-Stage Liver Disease (MELD) scores
and Child–Pugh classification were determined.
Standard institutional follow-up post-TIPS placement
included an ultrasound (US) at 2 weeks, 3 months, 6 months,
1 year, and then annually. Portal pressure gradients were
checked only at the time of TIPs placement, or if a revision
was required. All patients had a documented reduction in the
portal pressure gradient of less than 12 mm Hg, after each
TACE intervention. TIPS venography was not routinely per-
formed unless a patient had abnormal US findings or devel-
oped clinical symptoms consistent with shunt dysfunction.
Prior to each TACE procedure, all patients underwent dedi-
cated cross-sectional imaging [contrast enhanced computed
tomography (CT) or magnetic resonance imaging (MRI)] to
evaluate TIPS patency, tumour characteristics and its relation-
ship to surrounding vasculature.
TACE procedure
All patients were pretreated with steroids, benedryl, anti-emetics
and prophylactic antibiotics. Under conscious sedation, access
to the common femoral artery was obtained using a standard
Seldinger technique followed by placement of a 5-French (F)
vascular sheath. First, a superior mesenteric and celiac arterio-
gram was performed to assess patency of the portal vein/TIPS,
directionality of portal venous flow, as well as to evaluate for
the potential of the aberrant hepatic arterial vasculature. A
3-F microcatheter was then advanced into the second or
third-order branches of the right or left hepatic artery. Selec-
tive chemoembolizaiton was performed using a standard pro-
tocol consisting of 100 mg of cisplatin (if available) (Baxter,
Glendale, CA, USA), 50 mg of doxorubicin (Pharmacia & Up-
john, Peapack, NJ, USA) and 10 mg of mitomycin-C (Super
Gen, Dublin, CA, USA) combined with Ethiodol (Guerbet
LLC, Bloomington, IN, USA) in a 1:1 ratio without polyvinyl
alcohol (PVA) particles. Owing to a drug shortage, six
patients did not receive cisplatin as part of their TACE regi-
men. Further, a history of thrombocytopenia in one patient
resulted in doxorubicin being withheld. In addition, as a
result of the sub-selective approach, complete delivery of the
chemotherapy-Ethiodol emulsion was restricted. An average of
60% (6 cc) of the total chemotherapy dose was utilized per
TACE. Successful embolization was defined as vascular stasis
in the tumour arterial branches. After delivery of the drug
emulsion, two patients had significant residual tumour arterial
flow, which required injection of PVA particles (150–
250 micron) to achieve complete stasis. Post procedure,
patients were observed overnight in the hospital and
discharged home the subsequent morning.
Follow-up
Post TACE, patients were seen in follow-up at 2 and
4–6 weeks. Liver function tests and tumour markers were
obtained. All patients underwent contrast-enhanced CT or
MRI at a median of 41 days [interquartile range (IQR): 37–60]
after each TACE procedure. The treatment response of targeted
lesions was characterized by the modified Response Evaluation
Criteria in Solid Tumors (mRECIST).15 The objective response
rate (OR) post TACE was defined as tumours that displayed
either a partial or complete response based on mRECIST
definitions.
Post-procedure hepatotoxicity was evaluated based on the
development of one of the hepatobiliary severe adverse events
(SAEs) defined by the National Cancer Institute Common Ter-
minology Criteria for Adverse Events (NCI CTCAE) version
4.03.16 Hepatotoxicity was recorded if at least one of the fol-
lowing abnormal laboratory values or clinical states was
observed within a 6-week period after the procedure: NCI
CTCAE grade 3 or 4 for serum levels of total bilirubin, aspar-
tate aminotransferase (AST), alanine aminotransferase (ALT),
the presence of severe symptoms of ascites, or clinical hepatic
failure. Overall morbidity was assessed according to the Cla-
vien–Dindo classification system.17 Grade III or higher compli-
cations were included in the study. Progression-free (PFS) and
overall survival (OS) were calculated from the date of first
TACE treatment to the date of radiographic evidence of disease
progression (PFS), or the date of death/last follow-up (OS).
Patients that underwent liver transplantation were noted as a
censored event.
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Statistical analysis
Discrete variables were reported as totals and frequencies,
whereas continuous data were described as median values 
IQR. Survival (months) was assessed using Kaplan–Meier
methods. Statistical analyses were performed with Stata/MP
10.0 for Windows (StataCorp, College Station, TX, USA).
Results
From 1999 to 2014, 16 patients with HCC and TIPS underwent
a total of 27 TACE procedures. Eight of the 16 patients required
at least two treatments (50%) while an additional three patients
(18.8%) underwent a third TACE session. All patients had con-
firmation of TIPS patency by contrast-enhanced imaging prior
undergoing TACE. The majority of patients were male (n = 12,
75%) and had a median age at the time of first TACE of
60.5 years (IQR: 52.5–67.5). Prior to initial TACE, the median
MELD score was 12.5 (7.5–13), with the vast majority being
either Childs Class A or B (n = 14, 87.5%). While current treat-
ment guidelines often advise against routine TACE in Childs
Class C patients, two individuals in the present series under-
went therapy. In both patients, a super selective TACE
approach involving only the third order or greater hepatic
artery branches was utilized in order to minimize exposure of
the normal hepatic parenchyma to the cytotoxic agents. Patient
and tumour characteristics are described in Table 1.
Procedure-related morbidity
Within 6 weeks of each TACE session, Clavien grade 3 or
higher complications occurred three times (11.1%, Table 2).
Of the 16 patients that underwent TACE, four patients
accounted for all reported SAE complications (25%). The most
common hepatobiliary serious adverse event (SAE) was the
development of ascites post TACE (n = 3, 11.1%). Hepatic
failure, which was defined as the evolution of encephalophathy
or asterixis, occurred in two patients (7.4%). A greater fre-
quency of per-procedure complications were observed during
subsequent TACE sessions (n = 5, 45.4%) as compared with
the initial treatment (n = 2, 12.5%). There were no peri-proce-
dural (within 30 days) deaths after TACE. Of the two patients
that were Childs Class C, one patient experienced reversible
SAEs after two of their three TACE sessions. The first SAE was
the development of encephalopathy that was controlled by lac-
tulose. The second SAE required paracentesis to resolve the
abdominal ascites. Lastly, for the two patients that required
PVA embolization, neither experienced a treatment-related
complication.
Survival after TACE
After TACE, by mRECIST criteria, two patients (12.5%) dem-
onstrated a complete response, seven patients (43.8%) experi-
enced a partial response, six (37.5%) had stable disease, and
one had disease progression (6.2%). The objective response
(complete + partial response) and disease control (complete +
partial response + stable disease) rate were 56.3% and 93.8%,
respectively. The median follow-up after TACE was
11.5 months (IQR: 9.5–15.75). Of the 16 patients, three went
on to liver transplantation, whereas two patients underwent
additional therapies after completion of TACE: one patient
required radiofrequency ablation of a segment 6 lesion; the sec-
ond patient underwent stereotactic body radiation therapy fol-
lowed by systemic therapy after demonstrating disease
progression post TACE.
The median PFS and OS after censoring for liver transplan-
tation was 9 and 22 months, respectively (Fig. 1). Additionally,
Table 1 Patient characteristics
Variable TIPS group (n = 16)
Median age at first TACE (IQR) 60.5 (52.5–67.5)
Male gender, n (%) 12 (75)
Cause of cirrhosis, n (%)
Viral Hepatitis 7 (43.8)
Alcohol 5 (31.2)
NASH 2 (12.5)
Other 2 (12.5)
TIPS indication, n (%)
Ascites 9 (56.2)
Bleeding 7 (43.8)
Median MELD Score following
TIPS Placement (IQR)
12 (10.5–13)
Time between TIPS and first
TACE, (months)
Median (IQR) 41 (7.5–53.5)
Child–Pugh Class at first TACE, n (%)
A 2 (12.5)
B 12 (75)
C 2 (12.5)
Median MELD Score at first TACE (IQR) 12.5 (7.5–13)
Median dominant tumour size, cm (IQR) 2.8 (1.9–4.5)
Number of tumours
Single 9 (56.2)
Multiple 7 (43.8)
BCLC Stage, n (%)
A 3 (18.8)
B 4 (25)
C 7 (43.7)
D 2 (12.5)
Number of TACE procedures, median (range) 1 (1–3)
TACE, transarterial chemoembolization; TIPS, transjugular intrahepatic
portosystemic shunt; NASH, non-alcoholic steatohepatitis; MELD,
Model for End-Stage Liver Disease; BCLC, Barcelona Clinic Liver
Cancer.
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at 1 year, the OS survival rate was 73.9%. When stratifying
patients by BCLC stage, all three BCLC stage A patients pro-
ceeded to transplantation. The remaining 13 patients were
either BCLC stage B (n = 4), C (n = 7) or D (n = 2) and
experienced a median OS of 22 months.
Discussion
Patients with HCC and a concomitant TIPS pose unique chal-
lenges to clinicians when attempting to identify effective treat-
ment options. While the presence of a TIPS traditionally
underscores a patients advanced liver disease, the altered hepa-
tic perfusion that results after TIPS placement also questions
whether TACE can remain a safe and effective strategy. In the
present study, TACE was successfully performed in a series of
HCC patients with TIPS with low morbidity and a similar sur-
vival benefit to historical controls. These results provide further
evidence to support an expanded role for TACE that now
includes patients with a TIPS.
The primary concern surrounding TACE in HCC patients
with a TIPS is the potential for treatment-related liver failure.
Owing to the decrease in portal venous flow, TACE possesses
the theoretical risk of causing further hepatic dysfunction
through the disruption of the arterial vasculature, which the
normal hepatic parenchyma is dependent upon. To date, there
have been five series that have investigated the safety of TACE
in HCC patients that possess a TIPS (Table 3).6,11–14 However,
a common theme shared among published series, and further
demonstrated in the present study, was the assessment of TIPS
patency prior to performing TACE. While no patient in the
current series had evidence of a non-functional TIPS before
TACE, in the absence of clinical symptoms (gastrointestinal
bleeding, ascites), routine interrogation by venography to assess
TIPS patency, or determination of portal pressure gradients is
unnecessary. The criteria to perform TACE in TIPS patients
should not be predicated on the presence of a well-function-
ing TIPS. Any residual portal venous flow redirected towards
the liver parenchyma as a result of a stenosis in the TIPS, has
the potential to decrease the associated risk of hepatic dys-
function/infarction. Instead, consideration into which TIPS
patients would be suitable candidates for TACE should
include those with a good performance status, absence of clin-
ical symptoms to suggest worsening liver dysfunction, along
with laboratory evidence demonstrating stable hepatic func-
tion. In the present study, patients treated demonstrated a sta-
ble MELD score after TIPS placement to the date of the first
TACE.
Unfortunately, there has been a wide variation in the
reported morbidity rates among published series. A plausible
explanation for the equivocal outcomes could be attributed to
the lack of a uniform TACE treatment protocol. Several studies
including the present have opted for a selective approach when
using embolic material (e.g. PVA, foam, sponge).12 The vast
majority of patients among these studies did not ultimately
receive particulate embolization. Rather, the attenuation of
Table 2 TACE-related morbidity among HCC patients with a TIPS
First TACE
(n = 16)
Subsequent
TACE
(n = 11)
All TACE
(n = 27)
Clavien Grade ≥III
complication, n (%)
0 3 (27.3) 3 (11.1)
Hepatobiliary severe adverse events
Total bilirubin, n (%)
Grade 3/4: Total
bilirubin > 3 9 ULN
0 2 (18.2) 2 (7.4)
AST, n (%)
Grade 3/4: AST >
5 9 ULN
0 0 0
ALT, n (%)
Grade 3/4: ALT >
5 9 ULN
0 0 0
Ascites, n (%)
Grade 3: severe
symptoms
requiring invasive
intervention
0 3 (27.3) 3 (11.1)
Hepatic failure, n (%)
Grade 3: asterixis,
mild encephalopathy
2 (12.5) 0 2 (7.4)
Mortality, n (%)
Within 30 days of
procedure
0 0 0
TACE, transarterial chemoembolization; HCC, Hepatocellular Carci-
noma; TIPS, transjugular intrahepatic portosystemic shunt.
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Figure 1 Overall survival of hepatocellular carcinoma (HCC)
patients with a intrahepatic portosystemic shunt (TIPS) after
Transarterial chemoembolization (TACE) (n = 16), censored for liver
transplantation (n = 3)
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vascular flow was achieved solely by the lipiodol emulsion. The
rationale behind omitting embolic particles is to reduce the
extent of ischemic necrosis of normal hepatic parenchyma that
could result after TACE. In the present study, two of 16
patients received PVA. While neither patient experienced a
complication, the overall morbidity rate of the collective cohort
was low (25%) and comparable to the series by Wang
(31.6%).12 Similarly, the study by Gaba et al.13 abandoned the
use of embolic material in their series and demonstrated an
11% morbidity rate. In contrast, the study by Kohi et al.11
reported the highest frequency of complications (70%). A
major procedural difference in this study, however, was the
administering of the gelatin sponge after TACE. Perhaps,
avoidance of embolic material in total may decrease the likeli-
hood of treatment-related toxicity in TIPS patients. Nonethe-
less, the results of the present study along with published series
would suggest that TACE can be safely performed for HCC
patients with TIPS.
A second concern among HCC patients with a TIPS is
whether overall TACE treatment efficacy is compromised.
TIPS placement has been shown to increase arterioportal
venous shunting, which may alter the retention rate of the
lipiodol–chemotherapy emulsion within the tumour, thereby
limiting the treatment success.7 For non-TIPS HCC patients,
prior studies that utilized a TACE regimen consisting of cis-
platin, doxorubicin and mitomycin-C, they have demon-
strated median OS survival rates ranging from 15 to
18 months after TACE.18,19 Therefore, it would be reasonable
to suggest that any patient with unresectable HCC treated
with TACE should achieve a survival rate similar to published
series. While limited by the small sample size and no com-
parison arm, treated patients that did not go on to transplan-
tation in the present study, experienced a median overall
survival of 22 months. As for the three patients that under-
went transplantation, TACE was delivered as a bridging ther-
apy while suitable organs became available. The average time
on the liver transplant wait list experienced by the three
patients was 11.7 months. Despite the presence of the TIPS,
TACE effectively controlled tumour growth as reflected by all
the patients remaining within Milan Criteria while awaiting
transplantation. Therefore, these results reflect that the pres-
ence of a TIPS does not necessarily compromise efficacy, is
safe and should be considered as an additional treatment
adjunct for this difficult patient population.
In conclusion, the present study provides further evidence
supporting locoregional therapies as a safe and effective ther-
apy for HCC patients with a TIPS. While several other series
have reported their outcomes surrounding this patient sub-
group, treatment-related morbidity has been variable, which
can be partially attributed to the lack of standardized proto-
cols. Although the omission of embolic particles may limit the
extent of ischaemic necrosis that occurs with TACE, it did not
appear to affect treatment efficacy. In fact, TACE without
embolic material has the potential to be a safer approach for
patients with TIPS as it spares normal hepatic parenchyma
from further damage. Therefore, the presence of a TIPS should
not preclude HCC patients from receiving a therapy that can
achieve a durable survival benefit.
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Table 3 Comparison in treatment related morbidity and survival outcomes among select series that utilized TACE for HCC patients with
a concomitant TIPS
Author (Year) No. of
patients
% of Childs-pugh
Class A/B patients
Treatment regimen Type of embolic
material
% Morbidity Median
survival
(months)b
Overall
survival at
1 year (%)
Current Study 16 88 Cisplatin, Doxorubicin,
Mitomycin-C
PVAa 25 18 73.9
Tesdal et al. (2006)6 6 83 Epirubicin +/- PEI None 50 NR NR
Kang et al. (2012) 20 90 Cisplatin Gelatin Sponge 5b 23 85
Kohi et al. (2013)11 10 80 Cisplatin, Doxorubicin,
Mitomycin-C
Gelatin Sponge† 70 NR 100
Gaba et al. (2013)13 6 100 Cisplatin, Doxorubicin,
Mitomycin-C
None 11 NR 71
Wang et al. (2014)12 17 NR Doxorubicin,
5-fluorouracil
Gelfoama 31.6 NR 88
TACE, transarterial chemoembolization; TIPS, transjugular intrahepatic portosystemic shunt; PEI, percutaneous ethanol injection; NR, not
reported.
aNot all patients received embolic material.
bThe complication rate not reported according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
definitions.
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